Genomic Testing
FOUNDATIONONE®HEME
- Cancer TypeHematologic Malignancies, Sarcomas
- Sample TypeFFPE, Peripheral Whole Blood, Bone Marrow Aspirate
- Results Expected3 weeks*
What is FoundationOne Heme?
FoundationOne Heme is a comprehensive genomic profiling test for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically relevant alterations, potential targeted therapies, available clinical trials, and quantitative biomarkers that may support immunotherapy clinical trial enrollment.
FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.
Overview
FoundationOne Heme
>400
genes interrogated
>30
select introns profiled
>250
RNA-sequenced genes
- A single test that detects the four main classes of genomic alterations for hematologic cancers and sarcomas
- Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
- Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision making and clinical trial enrollment
Publications
FoundationOne Heme has been validated to detect all four classes of genomic alterations.
Published Clinical Study
Patient-derived xenotransplants (PDX) can recapitulate the genetic driver landscape of acute leukemias
These data emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.
Published Clinical Study
Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib
This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.
Explore a selection of the 300+ articles we've published since our founding.
Order FoundationOne Heme
We provide physicians with several options for ordering FoundationOne Heme for patients including online, fax, and e-mail. Physicians must first complete a test requisition form to start the process and can expect results within 3 weeks from the time a specimen is received.

Providers
FoundationOne Heme can be ordered online, by fax, or by phone. Please review and complete the provider resources before ordering.
Provider Resources
- Foundation Medicine Test Requisition Form
- Foundation Medicine Test Requisition Form Instructions
- FoundationOne Heme Technical Specifications and Test Overview
- FoundationOne Heme Specimen Instructions
- FoundationOne Heme Sample Type Recommendations
- Medicare Advanced Beneficiary Notice (ABN)
- ABN Information for Foundation Medicine Tests
Patients
FoundationOne Heme is ordered by your healthcare provider and we offer financial assistance for those who qualify. Download our form or apply online and speak with your healthcare provider today.
Patient Resources
Questions? We’re here to help.
Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.
We have even more to offer.
Learn more about our other tests, FoundationOne®Liquid, FoundationOne®CDx, or explore insights and trials or partnerships.
* Typical turnaround time from receipt of specimen is three weeks